Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

THE TRUTH ABOUT: Skye bioscience advances position in competitive obesity market with promising data | History Defined

Diet,And,Dieting.,Beauty,Slim,Female,Body,Use,Tape,Measure.

On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

In the first study, nimacimab matched or exceeded the weight loss of Novo Nordisk's (NYSE:NVO) monlunabant while showing superior post-treatment maintenance.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.